Leerink Partnrs Forecasts Penumbra’s Q1 Earnings (NYSE:PEN)

Penumbra, Inc. (NYSE:PEN) – Equities research analysts at Leerink Partnrs reduced their Q1 2025 earnings per share estimates for shares of Penumbra in a research report issued on Tuesday, February 18th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings per share of $0.69 for the quarter, down from their prior estimate of $0.83. The consensus estimate for Penumbra’s current full-year earnings is $3.67 per share. Leerink Partnrs also issued estimates for Penumbra’s Q2 2025 earnings at $0.83 EPS, FY2025 earnings at $3.61 EPS and FY2026 earnings at $5.54 EPS.

Penumbra (NYSE:PEN) last released its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.09. The business had revenue of $315.52 million during the quarter, compared to analyst estimates of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%.

PEN has been the subject of several other reports. Robert W. Baird raised their price objective on Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a research note on Wednesday. Royal Bank of Canada raised their target price on Penumbra from $285.00 to $313.00 and gave the stock an “outperform” rating in a research report on Wednesday. Canaccord Genuity Group raised their target price on Penumbra from $323.00 to $340.00 and gave the stock a “buy” rating in a research report on Wednesday. Needham & Company LLC reaffirmed a “hold” rating on shares of Penumbra in a research report on Wednesday. Finally, BTIG Research raised their target price on Penumbra from $232.00 to $270.00 and gave the stock a “buy” rating in a research report on Tuesday, November 26th. Three equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $292.64.

Penumbra Stock Performance

PEN opened at $292.52 on Friday. The firm has a market cap of $11.27 billion, a PE ratio of 860.35, a P/E/G ratio of 2.83 and a beta of 0.53. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. The business has a fifty day simple moving average of $259.09 and a 200-day simple moving average of $227.84. Penumbra has a fifty-two week low of $148.00 and a fifty-two week high of $310.00.

Insider Activity

In other news, CEO Adam Elsesser sold 15,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $242.96, for a total value of $3,644,400.00. Following the sale, the chief executive officer now directly owns 837,582 shares of the company’s stock, valued at approximately $203,498,922.72. This trade represents a 1.76 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Harpreet Grewal sold 167 shares of Penumbra stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $241.28, for a total value of $40,293.76. Following the sale, the director now directly owns 8,530 shares in the company, valued at approximately $2,058,118.40. This trade represents a 1.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,219 shares of company stock valued at $4,426,439. 5.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Penumbra

A number of institutional investors have recently added to or reduced their stakes in the company. FMR LLC grew its position in Penumbra by 2.1% during the third quarter. FMR LLC now owns 5,896,396 shares of the company’s stock worth $1,145,729,000 after buying an additional 121,465 shares in the last quarter. Champlain Investment Partners LLC boosted its holdings in Penumbra by 20.6% during the third quarter. Champlain Investment Partners LLC now owns 1,547,972 shares of the company’s stock valued at $300,786,000 after purchasing an additional 264,122 shares in the last quarter. State Street Corp boosted its holdings in Penumbra by 0.3% during the third quarter. State Street Corp now owns 1,236,671 shares of the company’s stock valued at $240,298,000 after purchasing an additional 3,863 shares in the last quarter. RTW Investments LP boosted its holdings in Penumbra by 8.4% during the fourth quarter. RTW Investments LP now owns 862,450 shares of the company’s stock valued at $204,815,000 after purchasing an additional 66,700 shares in the last quarter. Finally, Baillie Gifford & Co. boosted its holdings in Penumbra by 23.4% during the fourth quarter. Baillie Gifford & Co. now owns 730,233 shares of the company’s stock valued at $173,416,000 after purchasing an additional 138,387 shares in the last quarter. 88.88% of the stock is owned by institutional investors and hedge funds.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.